| 1 | whether | 48,210 |
| 2 | eleven-year-old | 2 |
| 3 | if/how | 2 |
| 4 | pn-mediated | 2 |
| 5 | psycho-biological | 2 |
| 6 | resistance.- | 2 |
| 7 | semi-objectively | 2 |
| 8 | wheter | 2 |
| 9 | 'non-functional | 1 |
| 10 | 10,836 | 1 |
| 11 | 12,041 | 1 |
| 12 | 13,556 | 1 |
| 13 | 14,030 | 1 |
| 14 | 17,605 | 1 |
| 15 | 2-thiophene-sulfonamides | 1 |
| 16 | 20-63-year-old | 1 |
| 17 | 3-hydroxypyridine-4-one | 1 |
| 18 | 41,226 | 1 |
| 19 | 5101-2003 | 1 |
| 20 | 5281 | 1 |
| 21 | 5ht1a-mediated | 1 |
| 22 | 7,186 | 1 |
| 23 | 70,373 | 1 |
| 24 | 77,319 | 1 |
| 25 | 84,759 | 1 |
| 26 | acu/ml | 1 |
| 27 | after-exercise | 1 |
| 28 | article-related | 1 |
| 29 | axon/synapse | 1 |
| 30 | better-tailored | 1 |
| 31 | blood-lead | 1 |
| 32 | bloodvessels | 1 |
| 33 | bolism | 1 |
| 34 | breaky | 1 |
| 35 | casseri | 1 |
| 36 | cetuximab- | 1 |
| 37 | charge-defined | 1 |
| 38 | ci-bra-downstream | 1 |
| 39 | cimt’s | 1 |
| 40 | community-provided | 1 |
| 41 | downdabigatran | 1 |
| 42 | during/around | 1 |
| 43 | echocardiographically-confirmed | 1 |
| 44 | eotaxin-3/cc | 1 |
| 45 | ester-loaded | 1 |
| 46 | excision- | 1 |
| 47 | exophthalmogeric | 1 |
| 48 | falconispalumbi | 1 |
| 49 | fluvially-dispersed | 1 |
| 50 | gammaretroviral | 1 |
| 51 | gdfeo₃-type | 1 |
| 52 | ghz-thz | 1 |
| 53 | how/when | 1 |
| 54 | hrn | 1 |
| 55 | human-factors-based | 1 |
| 56 | hypercholesterolaemia-induced | 1 |
| 57 | if/when | 1 |
| 58 | iflow-dose | 1 |
| 59 | incording | 1 |
| 60 | iris/eyelash | 1 |
| 61 | lagerstroemiae | 1 |
| 62 | left-helical | 1 |
| 63 | main-plot | 1 |
| 64 | maternal-independent | 1 |
| 65 | mattei | 1 |
| 66 | meti-r | 1 |
| 67 | mg/apheresis | 1 |
| 68 | mg/kg/min/µu/ml | 1 |
| 69 | microvue | 1 |
| 70 | ml/min/dl | 1 |
| 71 | ml/mq | 1 |
| 72 | mono-phosphate | 1 |
| 73 | more-integrative | 1 |
| 74 | n-acetyltransferase1 | 1 |
| 75 | nda-labelled | 1 |
| 76 | nf-groups | 1 |
| 77 | nicotine-opioid | 1 |
| 78 | nonperturbatively | 1 |
| 79 | np-impacts | 1 |
| 80 | off-laser | 1 |
| 81 | oro-cecal | 1 |
| 82 | ovothiol | 1 |
| 83 | oxidative-related | 1 |
| 84 | peer-supported | 1 |
| 85 | pirfenidone-induced | 1 |
| 86 | plasma-sheath | 1 |
| 87 | proximity-induced | 1 |
| 88 | prrrs | 1 |
| 89 | race-driven | 1 |
| 90 | recipient-based | 1 |
| 91 | ruscogenin | 1 |
| 92 | sdt-grounded | 1 |
| 93 | sealant/prr | 1 |
| 94 | self-reorganization | 1 |
| 95 | single-allele | 1 |
| 96 | squill | 1 |
| 97 | strumenti | 1 |
| 98 | szenario | 1 |
| 99 | tissue/cell-specific | 1 |
| 100 | treatment.analyses | 1 |
| 101 | ultra-sonically | 1 |
| 102 | ultraviolet-filtering | 1 |
| 103 | underperformers | 1 |
| 104 | vzv-prophylaxis | 1 |
| 105 | within-subgroup | 1 |
| 106 | yoshitomi | 1 |
| 1 | 'non-functional | 1 |
| 2 | 10,836 | 1 |
| 3 | 12,041 | 1 |
| 4 | 13,556 | 1 |
| 5 | 14,030 | 1 |
| 6 | 17,605 | 1 |
| 7 | 2-thiophene-sulfonamides | 1 |
| 8 | 20-63-year-old | 1 |
| 9 | 3-hydroxypyridine-4-one | 1 |
| 10 | 41,226 | 1 |
| 11 | 5101-2003 | 1 |
| 12 | 5281 | 1 |
| 13 | 5ht1a-mediated | 1 |
| 14 | 7,186 | 1 |
| 15 | 70,373 | 1 |
| 16 | 77,319 | 1 |
| 17 | 84,759 | 1 |
| 18 | acu/ml | 1 |
| 19 | after-exercise | 1 |
| 20 | article-related | 1 |
| 21 | axon/synapse | 1 |
| 22 | better-tailored | 1 |
| 23 | blood-lead | 1 |
| 24 | bloodvessels | 1 |
| 25 | bolism | 1 |
| 26 | breaky | 1 |
| 27 | casseri | 1 |
| 28 | cetuximab- | 1 |
| 29 | charge-defined | 1 |
| 30 | ci-bra-downstream | 1 |
| 31 | cimt’s | 1 |
| 32 | community-provided | 1 |
| 33 | downdabigatran | 1 |
| 34 | during/around | 1 |
| 35 | echocardiographically-confirmed | 1 |
| 36 | eleven-year-old | 2 |
| 37 | eotaxin-3/cc | 1 |
| 38 | ester-loaded | 1 |
| 39 | excision- | 1 |
| 40 | exophthalmogeric | 1 |
| 41 | falconispalumbi | 1 |
| 42 | fluvially-dispersed | 1 |
| 43 | gammaretroviral | 1 |
| 44 | gdfeo₃-type | 1 |
| 45 | ghz-thz | 1 |
| 46 | how/when | 1 |
| 47 | hrn | 1 |
| 48 | human-factors-based | 1 |
| 49 | hypercholesterolaemia-induced | 1 |
| 50 | if/how | 2 |
| 51 | if/when | 1 |
| 52 | iflow-dose | 1 |
| 53 | incording | 1 |
| 54 | iris/eyelash | 1 |
| 55 | lagerstroemiae | 1 |
| 56 | left-helical | 1 |
| 57 | main-plot | 1 |
| 58 | maternal-independent | 1 |
| 59 | mattei | 1 |
| 60 | meti-r | 1 |
| 61 | mg/apheresis | 1 |
| 62 | mg/kg/min/µu/ml | 1 |
| 63 | microvue | 1 |
| 64 | ml/min/dl | 1 |
| 65 | ml/mq | 1 |
| 66 | mono-phosphate | 1 |
| 67 | more-integrative | 1 |
| 68 | n-acetyltransferase1 | 1 |
| 69 | nda-labelled | 1 |
| 70 | nf-groups | 1 |
| 71 | nicotine-opioid | 1 |
| 72 | nonperturbatively | 1 |
| 73 | np-impacts | 1 |
| 74 | off-laser | 1 |
| 75 | oro-cecal | 1 |
| 76 | ovothiol | 1 |
| 77 | oxidative-related | 1 |
| 78 | peer-supported | 1 |
| 79 | pirfenidone-induced | 1 |
| 80 | plasma-sheath | 1 |
| 81 | pn-mediated | 2 |
| 82 | proximity-induced | 1 |
| 83 | prrrs | 1 |
| 84 | psycho-biological | 2 |
| 85 | race-driven | 1 |
| 86 | recipient-based | 1 |
| 87 | resistance.- | 2 |
| 88 | ruscogenin | 1 |
| 89 | sdt-grounded | 1 |
| 90 | sealant/prr | 1 |
| 91 | self-reorganization | 1 |
| 92 | semi-objectively | 2 |
| 93 | single-allele | 1 |
| 94 | squill | 1 |
| 95 | strumenti | 1 |
| 96 | szenario | 1 |
| 97 | tissue/cell-specific | 1 |
| 98 | treatment.analyses | 1 |
| 99 | ultra-sonically | 1 |
| 100 | ultraviolet-filtering | 1 |
| 101 | underperformers | 1 |
| 102 | vzv-prophylaxis | 1 |
| 103 | wheter | 2 |
| 104 | whether | 48,210 |
| 105 | within-subgroup | 1 |
| 106 | yoshitomi | 1 |
| 1 | resistance.- | 2 |
| 2 | cetuximab- | 1 |
| 3 | excision- | 1 |
| 4 | 14,030 | 1 |
| 5 | 12,041 | 1 |
| 6 | 5281 | 1 |
| 7 | n-acetyltransferase1 | 1 |
| 8 | 5101-2003 | 1 |
| 9 | 70,373 | 1 |
| 10 | 17,605 | 1 |
| 11 | 41,226 | 1 |
| 12 | 10,836 | 1 |
| 13 | 13,556 | 1 |
| 14 | 7,186 | 1 |
| 15 | 77,319 | 1 |
| 16 | 84,759 | 1 |
| 17 | eotaxin-3/cc | 1 |
| 18 | tissue/cell-specific | 1 |
| 19 | exophthalmogeric | 1 |
| 20 | blood-lead | 1 |
| 21 | hypercholesterolaemia-induced | 1 |
| 22 | pirfenidone-induced | 1 |
| 23 | proximity-induced | 1 |
| 24 | ester-loaded | 1 |
| 25 | community-provided | 1 |
| 26 | sdt-grounded | 1 |
| 27 | nda-labelled | 1 |
| 28 | echocardiographically-confirmed | 1 |
| 29 | charge-defined | 1 |
| 30 | better-tailored | 1 |
| 31 | human-factors-based | 1 |
| 32 | recipient-based | 1 |
| 33 | fluvially-dispersed | 1 |
| 34 | 5ht1a-mediated | 1 |
| 35 | pn-mediated | 2 |
| 36 | article-related | 1 |
| 37 | oxidative-related | 1 |
| 38 | peer-supported | 1 |
| 39 | nicotine-opioid | 1 |
| 40 | 20-63-year-old | 1 |
| 41 | eleven-year-old | 2 |
| 42 | during/around | 1 |
| 43 | lagerstroemiae | 1 |
| 44 | single-allele | 1 |
| 45 | 3-hydroxypyridine-4-one | 1 |
| 46 | gdfeo₃-type | 1 |
| 47 | after-exercise | 1 |
| 48 | iflow-dose | 1 |
| 49 | axon/synapse | 1 |
| 50 | mono-phosphate | 1 |
| 51 | microvue | 1 |
| 52 | more-integrative | 1 |
| 53 | incording | 1 |
| 54 | ultraviolet-filtering | 1 |
| 55 | iris/eyelash | 1 |
| 56 | plasma-sheath | 1 |
| 57 | falconispalumbi | 1 |
| 58 | mattei | 1 |
| 59 | yoshitomi | 1 |
| 60 | casseri | 1 |
| 61 | strumenti | 1 |
| 62 | oro-cecal | 1 |
| 63 | psycho-biological | 2 |
| 64 | left-helical | 1 |
| 65 | 'non-functional | 1 |
| 66 | gammaretroviral | 1 |
| 67 | ml/min/dl | 1 |
| 68 | squill | 1 |
| 69 | acu/ml | 1 |
| 70 | mg/kg/min/µu/ml | 1 |
| 71 | ovothiol | 1 |
| 72 | ci-bra-downstream | 1 |
| 73 | bolism | 1 |
| 74 | downdabigatran | 1 |
| 75 | if/when | 1 |
| 76 | how/when | 1 |
| 77 | race-driven | 1 |
| 78 | ruscogenin | 1 |
| 79 | self-reorganization | 1 |
| 80 | hrn | 1 |
| 81 | szenario | 1 |
| 82 | within-subgroup | 1 |
| 83 | ml/mq | 1 |
| 84 | meti-r | 1 |
| 85 | whether | 48,210 |
| 86 | off-laser | 1 |
| 87 | wheter | 2 |
| 88 | sealant/prr | 1 |
| 89 | 2-thiophene-sulfonamides | 1 |
| 90 | treatment.analyses | 1 |
| 91 | mg/apheresis | 1 |
| 92 | vzv-prophylaxis | 1 |
| 93 | bloodvessels | 1 |
| 94 | nf-groups | 1 |
| 95 | underperformers | 1 |
| 96 | prrrs | 1 |
| 97 | np-impacts | 1 |
| 98 | cimt’s | 1 |
| 99 | maternal-independent | 1 |
| 100 | main-plot | 1 |
| 101 | if/how | 2 |
| 102 | breaky | 1 |
| 103 | nonperturbatively | 1 |
| 104 | semi-objectively | 2 |
| 105 | ultra-sonically | 1 |
| 106 | ghz-thz | 1 |